Cell-seeded porous lung hydrogel sealant

US2019224364A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2019224364-A1
Application numberUS-201916371703-A
CountryUS
Kind codeA1
Filing dateApr 1, 2019
Priority dateOct 6, 2016
Publication dateJul 25, 2019
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are a biosealant system and method for treatment of a pulmonary air leak comprising applying the biosealant system to the locus of the air leak.

First claim

Opening claim text (preview).

What is claimed is: 1 . A biosealant composition comprising an extracellular matrix hydrogel and a thermogel; wherein the extracellular matrix hydrogel comprises a first extracellular matrix protein, an unbranched polysaccharide, and an elastic protein; and wherein the thermogel comprises a gelatinous material and a cross-linking enzyme in an amount sufficient to result in gelation of the thermogel at a temperature from about 35° C. to 37° C. 2 . The biosealant of claim 1 , wherein the first extracellular matrix protein is collagen, wherein the elastic protein is elastin, and wherein the unbranched polysaccharide is sulfated glycosaminoglycan. 3 . The biosealant of claim 1 , wherein the cross-linking enzyme is transglutaminase. 4 . The biosealant of claim 1 , wherein the extracellular matrix hydrogel also comprises additional therapeutics including cells, microsomes, peptides, or drugs. 5 . The biosealant of claim 1 , wherein the cross-linking enzyme is present in an amount from about 0.5 units/mL to 5 units/mL. 6 . The biosealant of claim 1 , wherein the gelatinous material is gelatin. 7 . The biosealant of claim 1 , wherein the thermogel comprises pores of diameter of about 0.025 mm to 90 mm. 8 . The biosealant of claim 1 , wherein the biosealant composition does not contain fibrin. 9 . The biosealant of claim 1 , wherein the first extracellular matrix protein is present in an amount from about 25% by weight to about 75% by weight of the total weight of the first extracellular matrix protein, unbranched polysaccharide, and elastic protein of the extracellular matrix hydrogel. 10 . The biosealant of claim 1 , wherein the unbranched polysaccharide is present in an amount from about 0.5% by weight to about 15% by weight of the total weight of the first extracellular matrix protein, unbranched polysaccharide, and elastic protein of the extracellular matrix hydrogel. 11 . The biosealant of claim 1 , wherein the elastic protein is present in an amount from about 25% by weight to about 75% by weight of the total weight of the first extracellular matrix protein, unbranched polysaccharide, and elastic protein of the extracellular matrix hydrogel. 12 . A method for sealing a puncture or wound in a tissue comprising applying a biosealant composition directly to the puncture or wound; wherein the biosealant composition comprising an extracellular matrix hydrogel and a thermogel; wherein the extracellular matrix hydrogel comprises a first extracellular matrix protein, an unbranched polysaccharide, and an elastic protein; and wherein the thermogel comprises a gelatinous material and a cross-linking enzyme in an amount sufficient to result in gelation of the thermogel at a temperature from about 35° C. to 37° C. 13 . The method of claim 12 , wherein the tissue is the lung. 14 . The method of claim 12 , wherein the first extracellular matrix protein is collagen, wherein the elastic protein is elastin, and wherein the unbranched polysaccharide is sulfated glycosaminoglycan. 15 . The method of claim 12 , wherein the gelatinous material is gelatin. 16 . The method of claim 12 , wherein the thermogel comprises pores of diameter of about 0.025 mm to 90 mm. 17 . The method of claim 12 , wherein the cross-linking enzyme is transglutaminase. 18 . A method of making a biosealant according to claim 1 comprising the steps of: mixing a first extracellular matrix protein, an unbranched polysaccharide, an elastic protein, and a first cross-linking enzyme to form an extracellular matrix hydrogel; mixing a gelatinous material in saline with a second cross-linking enzyme to form a thermogel; heating the thermogel to about 52° C. to 55° C.; and making the thermogel porous. 19 . The method of claim 18 , wherein the step of making the thermogel porous comprises applying a bubbling gas with a bubble generator through the thermogel material. 20 . The method of claim 18 , wherein the first extracellular matrix protein is collagen, wherein the elastic protein is elastin, wherein the unbranched polysaccharide is sulfated glycosaminoglycan, and wherein the first and second cross-linking enzyme is transglutaminase.

Assignees

Inventors

Classifications

  • Collagen · CPC title

  • Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106 · CPC title

  • containing macromolecular fillers · CPC title

  • Mixtures of macromolecular materials · CPC title

  • Gelatin · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2019224364A1 cover?
Disclosed are a biosealant system and method for treatment of a pulmonary air leak comprising applying the biosealant system to the locus of the air leak.
Who is the assignee on this patent?
Univ Columbia
What technology area does this patent fall under?
Primary CPC classification A61L24/0031. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Jul 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).